Feedback

Browsing by E


Use an asterisk (*) for partial word searches (e.g. pemph*)

101 results found.

1.
2.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
3.
4.
5.
Ordering Recommendation:   No alternative testing available in the U.S. See Inactivation Notification.
6.
Ordering Recommendation:   No alternative testing available in the U.S. See Inactivation Notification.
7.
Ordering Recommendation:   No alternative testing available in the U.S. See Inactivation Notification.
8.
Ordering Recommendation:   No alternative testing available in the U.S. See Inactivation Notification.
9.
10.
11.
Ordering Recommendation:   Aids in prognostication and therapeutic decisions for neoplasms where amplification has been demonstrated.
12.
Ordering Recommendation:   Predicts response to tyrosine kinase inhibitor (TKI) therapy.
13.
Ordering Recommendation:   Preferred molecular (DNA) test to confirm a diagnosis of Ehlers-Danlos type VI following clinical and/or biochemical presentation. For initial testing for EDS VI, refer to Ehlers-Danlos Syndrome Type VI Screen (0080351). This testing is NOT recommended to rule out other types of EDS.
14.
Ordering Recommendation:   Initial test to diagnose or rule out Ehlers-Danlos Syndrome, Type VI A (kyphoscoliotic type). This testing is NOT recommended to screen for other types of EDS.
15.
Ordering Recommendation:   Preferred panel for diagnosing possible tick-borne disease (ie, Anaplasmosis or Ehrlichiosis) during the acute phase of the disease.
16.
Ordering Recommendation:   Diagnose infection from Ehrlichia chaffeensis.
17.
Ordering Recommendation:   Most useful to detect antibodies during convalescent phase of disease. PCR testing is preferred; refer to Tick-Borne Disease Panel by PCR, Blood (2008670) or Ehrlichia and Anaplasma Species by Real-Time PCR (2007862).
18.
Ordering Recommendation:   Most useful to detect antibodies during acute phase of disease; recommend concurrent testing with IgG E. chaffeensis. PCR testing is preferred; refer to Tick-Borne Disease Panel by PCR, Blood (2008670) or Ehrlichia and Anaplasma Species by Real-Time PCR (2007862).
19.
Ordering Recommendation:   Diagnostic or carrier testing for EIF2AK4-associated pulmonary capillary hemangiomatosis (PCH) or pulmonary veno-occlusive disease (PVOD).
20.
21.
22.
23.
24.
25.
26.
27.
Ordering Recommendation:   Confirm suspected hereditary endocrine cancer syndrome in individuals with personal or family history of endocrine cancer.
28.
Ordering Recommendation:   Do not use in IgA-deficient individuals; acceptable single screening test for celiac disease. Acceptable follow-up test for weakly positive or negative tissue transglutaminase (tTG) IgA screen. Celiac Disease Reflexive Cascade (2008114) or Tissue Transglutaminase (tTG) Antibody, IgA (0097709) testing is the preferred testing for screening at-risk patients for celiac disease who should undergo small bowel biopsy to confirm disease.
29.
Ordering Recommendation:   Use in IgA-deficient individuals; acceptable single screening test for celiac disease. Acceptable follow-up test for weakly positive or negative tissue transglutaminase IgG screen. Celiac Disease Reflexive Cascade (2008114) is the preferred screening test for individuals with high suspicion for IgA deficiency or patients at-risk for celiac disease who should undergo small bowel biopsy to confirm disease.
30.
Ordering Recommendation:   Quantitative test used to detect gram-negative endotoxins in hemodialysis reuse water.
31.
32.
Ordering Recommendation:   Test for persistent diarrhea (>14 days) or known risk factors if E. histolytica is the suspected infectious agent.
33.
34.
35.
36.
37.
38.
Ordering Recommendation:   ()Identify eosinophil involvement by staining for eosinophil granule major basic protein 1 (eMBP1) and eosinophil-derived neurotoxin (EDN) to detect both cellular localization and extracellular deposition.()Eosinophil granule proteins are toxic to tissues and cells and may be pathogenic in disease but not recognized when deposited outside of morphologically identifiable intact eosinophils.
39.
Ordering Recommendation:   Aids in diagnosis and classification of hematopoietic neoplasms presenting with prominent eosinophilia. Does not detect rearrangements associated with chronic myelogenous leukemia.
40.
41.
42.
Ordering Recommendation:   ()Order with celiac disease serology testing for patient with possible dermatitis herpetiformis. IgA epidermal transglutaminase (transglutaminase 3 or TG3) antibodies are pathogenic in dermatitis herpetiformis, and an increased level is distinctly characteristic of the disorder.()For initial diagnosis and to discriminate among the immunobullous skin diseases in patients suspected or known to have any type of immunobullous disease, order concurrently with testing for epithelial cell surface antibody (0090299) or refer to antibody panel tests for pemphigoid (0092001) and pemphigus (0090650).
43.
Ordering Recommendation:   ()Assess and monitor patient with linear IgA disease, including linear IgA bullous dermatosis and positive IgA BMZ antibodies, either epidermal (roof) pattern or dermal (floor) pattern.()Consider ordering concurrently with IgG antibody testing for epithelial BMZ (0092056), bullous pemphigoid (BP 180 & 230) antigens (0092566), and/or collagen type VII (2010905).
44.
Ordering Recommendation:   ()Monitor disease in patient with pemphigoid or epidermolysis bullosa acquisita who has positive IgG BMZ antibodies by indirect immunofluorescence, either epidermal (roof) pattern or dermal (floor) pattern, on split skin substrate.()Consider ordering concurrently with IgG antibody testing for bullous pemphigoid (BP180 & 230) antigens (0092566) and/or collagen type VII (2010905).()May use to screen for pemphigoid and other immunobullous diseases; however, this test has decreased sensitivity and specificity when compared to the panel tests for pemphigus antibodies (0090650) or pemphigoid antibodies (0092001) and will not detect IgA BMZ antibodies.
45.
Ordering Recommendation:   ()Monitor patient with pemphigus who has positive IgG cell surface antibodies, but normal IgG desmoglein 1 and/or 3 antibody levels.()For initial diagnosis and disease monitoring, the preferred test is the pemphigus antibody panel (0090650); panel components include IgG epithelial cell surface antibodies and IgG desmoglein 1 and 3.()May use to screen for pemphigus or pemphigoid; however, this test has decreased sensitivity and specificity when compared to the panel tests for pemphigus antibodies (0090650) or pemphigoid antibodies (0092001).
46.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
47.
Ordering Recommendation:   ()General screen for immunobullous diseases. Test includes IgG and IgA BMZ antibodies (pemphigoid, epidermolysis bullosa acquisita, linear IgA disease) and IgG and IgA cell surface antibodies (IgG and IgA pemphigus subtypes).()Consider ordering concurrently with IgG bullous pemphigoid (BP180 & 230) antigens (0092566) for suspected pemphigoid and/or IgG desmoglein 1 and 3 antibodies (0090649) for suspected pemphigus.()For more sensitive and specific testing for pemphigoid or pemphigus, refer to antibody panels for pemphigus (0090650) or pemphigoid (0092001).
48.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
49.
Ordering Recommendation:   Preferred test for confirming Primary Familial or Congenital Polycythemia (PFCP).
50.
51.
Ordering Recommendation:   Aids in diagnosis of primary Epstein-Barr virus infectious mononucleosis after a suspected false-negative heterophile antibody (Monospot) test.
52.
Ordering Recommendation:   Aids in determining past or present Epstein-Barr virus (EBV) infection as well as susceptibility to future EBV infection. May be used in conjunction with EBV nuclear antigen to diagnose primary EBV infectious mononucleosis.
53.
Ordering Recommendation:   May aid in the diagnosis of acute Epstein-Barr virus (EBV) infection and EBV reactivation in conjunction with other serologic studies. Molecular tests are preferred to detect EBV reactivation. Not a stand-alone test.
54.
Ordering Recommendation:   Order to document past Epstein-Barr virus (EBV) exposure or, in conjunction with other serologic tests, diagnose primary EBV infectious mononucleosis.
55.
Ordering Recommendation:   Do not use to diagnose Epstein-Barr virus infectious mononucleosis. May aid in the detection and prognosis of nasopharyngeal carcinoma.
56.
Ordering Recommendation:   Order to document past Epstein-Barr virus exposure or, in conjunction with other serologic tests, diagnose primary EBV infectious mononucleosis.
57.
Ordering Recommendation:   Do not use for diagnosis of Epstein-Barr virus infectious mononucleosis. May aid in the detection and prognosis of nasopharyngeal carcinoma.
58.
Ordering Recommendation:   Aids in the diagnosis of primary Epstein-Barr virus infectious mononucleosis, in conjunction with other serologic tests. Not a stand-alone test.
59.
Ordering Recommendation:   Do not use for diagnosis of infectious mononucleosis. Order to detect Epstein-Barr virus (EBV) in individuals suspected of having EBV-related disease.
60.
Ordering Recommendation:   Quantify Epstein-Barr virus (EBV) viral load as an aid in monitoring EBV-related disease.
61.
Ordering Recommendation:   Quantify Epstein-Barr virus (EBV) viral load as an aid in monitoring EBV-related disease.
62.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
63.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
64.
Ordering Recommendation:   ()Aids in prediction of response to trastuzumab (Herceptin) therapy in patients with breast cancer.()Alternate test to confirm equivocal fluorescence in situ hybridization (FISH) result.
65.
Ordering Recommendation:   ()Aids in prediction of response to trastuzumab (Herceptin) therapy in patients with breast or gastric cancer.()Use to confirm equivocal HercepTest or 4B5 immunohistochemistry (IHC) result (2+).
66.
Ordering Recommendation:   Resolves discrepancies between ERBB2 FISH, dual-ISH and immunohistochemistry (IHC) results.
67.
Ordering Recommendation:   Screen for erythropoietic protoporphyria (EPP) in patients with cutaneous photosensitivity.
68.
Ordering Recommendation:   Initial screening test when evaluating for polycythemia and determining eligibility for erythropoietin therapy in anemia due to chronic renal failure.
69.
70.
71.
Ordering Recommendation:   Suitable for measurement of estradiol in adult premenopausal women. In all other groups, the preferred test is Estrogens, Fractionated by Tandem Mass Spectrometry (HPLC) test (0093248).
72.
Ordering Recommendation:   Suitable for measurement of estradiol in men, children, or postmenopausal women. Preferred test for adult premenopausal women is Estradiol, Adult Premenopausal Female, Serum or Plasma (0070045).
73.
Ordering Recommendation:   Screening test for fetal aneuploidy in conjunction with other biomarkers and ultrasonography. Indicator of fetal well-being and placental function.
74.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
75.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
76.
Ordering Recommendation:   Recommended test for evaluating endogenous estrogen status in postmenopausal women, men, or children.
77.
Ordering Recommendation:   Rarely indicated. If serum estrone measurement is needed, preferred test is Estrogens, Fractionated by Tandem Mass Spectrometry (0093248).
78.
79.
80.
Ordering Recommendation:   Serum test to identify acute alcohol ingestion.
81.
Ordering Recommendation:   Urine test to identify acute alcohol ingestion.
82.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
83.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
84.
Ordering Recommendation:   Urine confirmation test to identify acute alcohol ingestion.
85.
Ordering Recommendation:   Urine screening and confirmation test to identify acute alcohol ingestion.
86.
Ordering Recommendation:   Aid in assessment of the etiology of anion gap acidosis. Determine whether ethylene glycol poisoning exists.
87.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
88.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
89.
Ordering Recommendation:   Diagnose members of the Ewing sarcoma family of tumors (ESFT); however, this assay does not identify the translocation partner.
90.
Ordering Recommendation:   Confirm histological diagnosis of Ewing sarcoma by detection of EWSR1-FLI1 and EWSR1-ERG fusions.
91.
Ordering Recommendation:   ()Preferred test to determine a genetic cause for the patient's medical condition. Full exome sequencing is performed on the patient's and parental samples. Parental samples are used to identify causativemutation(s) and de novo variants.()Parental samples are required to interpret the patient's results; submit each parental sample as Exome Sequencing, Familial Control, Tracking (2006340).
92.
Ordering Recommendation:   ()Acceptable test to determine a genetic cause for the patient's medical condition when both parental samples are not available. Full exome sequencing is only performed for the patient. Targeted variant testing is performed on parental samples to determine the origin and significance of DNA variants identified in the patient.()Parental samples are required to interpret the patient's result, submit each parental sample as Genomics Patient Control (2007820). There is no additional charge for parental testing.
93.
Ordering Recommendation:   Preconception and prenatal carrier screening. Refer to "Additional Technical Information" document for mutations tested.
94.
Ordering Recommendation:   Preconception and prenatal carrier screening. Refer to "Additional Technical Information" document for mutations tested.
95.
Ordering Recommendation:   Preconception and prenatal carrier screening. Refer to "Additional Technical Information" document for mutations tested.
96.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
97.
Ordering Recommendation:   May be ordered as first-tier genetic test for hearing loss, or after GJB2, GJB6, and mitochondrial mutation testing has been performed.
98.
Ordering Recommendation:   Most comprehensive genetic test for nonsyndromic and syndromic hearing loss. May be ordered as first-tier genetic test for hearing loss, or after GJB2, GJB6, and mitochondrial mutation testing has been performed.
99.
100.
101.